Product Images Everolimus

This is a description for Everolimus Tablets with a concentration of 7.5 mg. The carton contains 4 blister cards, each with 7 tablets and the NDC assigned to this medication is 49884-127-91. The tablets are for oral use and are only available with a prescription. It is important to store the medication in a place that ranges from 15° to 30°C (59° to 86°F), shielded from light and moisture. The manufacturer is Par Pharmaceutical, and for further information, call the number 1-800-828-9393. Always keep this and all drugs out of children's reach.*

Everolimus Tablet is a medication produced by PAR Pharmaceutical. The medication is intended to be taken orally and comes in the form of a tablet. The labeling includes the address of the manufacturer in New York. There are several references to an "empty cavity" but it is not clear what this is referring to.*

This is a description of a medication called Everolimus Tablets. It comes in a pack containing 28 tablets, divided into 4 blister cards of 7 tablets each. Each tablet contains 10mg of everolimus. The medication is intended for oral use only, and the dosage should be referred to from the package insert. The manufacturer's contact information is also given.*

The text describes the Progression-free Survival Probability of patients who were administered Everolimus 10mg + exemestane or Placebo-exemestane. The Kaplan-Meier medians were 7.8 months for Everolimus and 32 months for Placebo. The Logrank p value was less than 0.001. The graph shows the censoring times for both groups of patients over a period of 0 to 28 months.*

This text provides results of a study comparing the effectiveness of Everolimus Tablets with Placebo in cancer treatments. It includes details on the probability of success, hazard ratio with 95% confidence interval, Logrank p-value, Kaplan-Meier medians, and censoring times. The study found that the Everolimus Tablets had a higher success rate with a median of 11.04 months compared to 4.60 months for Placebo. The graph also shows the percentage of censoring times for the two treatments over time.*

This is a report of a clinical trial comparing Everolimus and Placebo. The analysis shows that Everolimus significantly prolongs the time until the occurrence of an event of interest (as measured by hazard ratio =0.33 with a 95% confidence interval of [0.25,0.43], and a log-rank p-value of <0.0001) compared to Placebo. Kaplan-Meier medians show that the median time for Everolimus is 4.9 months, whereas for Placebo, it is 1.9 months. The graph shows the proportion of subjects who had an event of interest over time for both groups. The study was conducted in at least two groups – Everolimus group with 277 subjects and Placebo group with139 subjects. The study is likely related to cancer or another chronic disease, but the details are unavailable from this text.*

This is an information leaflet regarding the storage of everolimus tablets. The tablets should be stored at a temperature of 25°C to 35°C (77°F) in their original container, and protected from light and moisture. Excursions are only permitted between 15°C to 30°C (59°F to 86°F). The manufacturer of this medication is PAR Pharmaceutical located in Chestnut Ridge, NY 10577. The product codes for the packaging are BLITS.G31-01 102116 and NOT)1 03 49884-119-529.*

This is a description of the medication Everolimus in tablet form. The medication comes in a carton containing 4 individual blister cards of 7 tablets each. Each tablet contains 2.5 mg of Everolimus. The tablets are for oral use and are only available by prescription. Patients who require more information about the medication can contact the manufacturer at 1-800-828-9393. The tablets should be stored at 25°C (77°F) and kept away from moisture, light, and children. The tablets are manufactured by Par Pharmaceutical in Chestnut Ridge, NY. Detailed information on dosages is included in the package insert, and it is recommended to consult with a healthcare professional before use.*

This text contains information related to the storage and protection of medications known as Everolimus Tablet, produced by PAR PHARMACEUTICAL, Chestnut Ridge, NY. The recommended storage temperature is 15°C to 30°C (59°F t0.86°F), and it must be kept in its original container and protected from light and moisture. Different batch numbers and phone numbers are also presented, but no additional information is provided about the medication itself.*

This is a description of a medication named Everolimus Tablets in its packaging. The medication comes in a carton that contains 4 blister cards of 7 tablets each, totaling 28 tablets. Each tablet is 5 mg and contains everolimus. The medication is for oral use only and is Rx only. The temperature for storing the medicine is between 15 to 30°C (59 to 86°F), and it should be kept in its original container, protected from light and moisture. The manufacturer is Par Pharmaceutical situated in Chestnut Ridge, NY 10977. The package insert contains dosage information. The customers can call 1-800-828-9393 for more information. The description also contains a cautionary note for keeping the drugs out of reach of children.*

This text contains information about Everolimus Tablet, available in 75mg and 7.5mg with storage instructions. It is manufactured by PAR PHARMACEUTICAL and should be stored at a temperature between 15°C to 30°C, protected from light and moisture. Excursions are permitted between 5°C to 8°C. The container should be kept in its original form. The text also contains batch and serial numbers.*